Jazz Pharmaceuticals PLC (JAZZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
Jazz Pharmaceuticals PLC (JAZZ) Earnings: Report Dates and Results
Jazz Pharmaceuticals (JAZZ) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Jazz Pharmaceuticals reported EPS of -$4.83, above the -$5.18 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
JAZZ has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 7.2% above the $6.64 reported for the quarter ended Dec 31, 2025.
JAZZ Earnings Call
The latest JAZZ earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, JAZZ beat 26 and missed 14. Revenue for the quarter ended Sep 30, 2026 was $1.24B, up 9.7% from $1.13B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$4.83 | -$5.18 | N/A | +6.76% | Beat | -169.1% | 13 | 0 up, 10 down | Nov 2, 2026 | $1.24B |
| Jun 30, 2026 | $4.89 | $5.06 | N/A | -3.36% | Miss | N/A | 17 | 0 up, 2 down | Aug 3, 2026 | $1.21B |
| Mar 31, 2026 | $6.34 | $4.66 | $3.75 - $5.62 | +36.05% | Beat | +277.4% | 15 | 5 up, 2 down | May 5, 2026 | $1.07B |
| Dec 31, 2025 | $6.64 | $6.51 | $5.95 - $7.55 | +2.05% | Beat | +0.6% | 13 | 6 up, 2 down | Feb 24, 2026 | $1.20B |
| Sep 30, 2025 | $6.99 | $4.80 | N/A | +45.63% | Beat | +5.7% | 16 | 1 up, 4 down | Nov 5, 2025 | $1.13B |
| Jun 30, 2025 | -$8.25 | -$6.25 | -$9.61 - $4.47 | -32.00% | Miss | -255.7% | 16 | 4 up, 3 down | Aug 5, 2025 | $1.05B |
| Mar 31, 2025 | $1.68 | $4.66 | $3.70 - $5.87 | -63.95% | Miss | -37.3% | 16 | 1 up, 4 down | May 6, 2025 | $897.80M |
| Dec 31, 2024 | $6.60 | $5.81 | $5.00 - $6.49 | +13.58% | Beat | +31.5% | 17 | 3 up, 2 down | Feb 25, 2025 | $1.09B |
| Sep 30, 2024 | $6.61 | $5.50 | $4.93 - $5.93 | +20.18% | Beat | +36.6% | 17 | 2 up, 1 down | Nov 6, 2024 | $1.05B |
| Jun 30, 2024 | $5.30 | $4.78 | $4.23 - $5.78 | +10.88% | Beat | +17.5% | 17 | 1 up, 2 down | Jul 31, 2024 | $1.02B |
| Mar 31, 2024 | $2.68 | $4.18 | $3.73 - $4.83 | -35.89% | Miss | -32.2% | 16 | 2 up, 2 down | May 1, 2024 | $901.98M |
| Dec 31, 2023 | $5.02 | $5.18 | $4.75 - $5.62 | -3.09% | Miss | N/A | 15 | 2 up, 0 down | Feb 28, 2024 | $1.01B |
| Sep 30, 2023 | $4.84 | $4.93 | $4.44 - $5.19 | -1.83% | Miss | -6.4% | 15 | 2 up, 1 down | Nov 8, 2023 | $972.14M |
| Jun 30, 2023 | $4.51 | $4.43 | $3.93 - $4.92 | +1.81% | Beat | +4.9% | 15 | 2 up, 0 down | Aug 9, 2023 | $957.32M |
| Mar 31, 2023 | $3.95 | $4.22 | $3.73 - $5.02 | -6.40% | Miss | +5.9% | 16 | 1 up, 0 down | May 10, 2023 | $892.81M |
| Dec 31, 2022 | -$0.07 | $0.32 | -$0.46 - $0.88 | -121.88% | Miss | -101.7% | 13 | 0 up, 2 down | Mar 1, 2023 | $972.12M |
| Sep 30, 2022 | $5.17 | $4.67 | $4.11 - $4.98 | +10.71% | Beat | +23.1% | 16 | 3 up, 0 down | Nov 9, 2022 | $940.65M |
| Jun 30, 2022 | $4.30 | $4.19 | $3.32 - $4.70 | +2.63% | Beat | +10.3% | 16 | 3 up, 1 down | Aug 3, 2022 | $932.88M |
| Mar 31, 2022 | $3.73 | $3.89 | $3.06 - $4.62 | -4.11% | Miss | -4.8% | 16 | 3 up, 0 down | May 4, 2022 | $813.72M |
| Dec 31, 2021 | $4.21 | $3.64 | $3.05 - $3.94 | +15.66% | Beat | +5.2% | 18 | 1 up, 1 down | Mar 1, 2022 | $896.73M |
| Sep 30, 2021 | $4.20 | $3.31 | $2.88 - $3.69 | +26.89% | Beat | -2.6% | 15 | 1 up, 0 down | Nov 9, 2021 | $838.12M |
| Jun 30, 2021 | $3.90 | $3.45 | $2.00 - $4.26 | +13.04% | Beat | +5.1% | 13 | N/A | Aug 3, 2021 | $751.81M |
| Mar 31, 2021 | $3.92 | $3.73 | $3.32 - $4.07 | +5.09% | Beat | +771.1% | 18 | N/A | May 4, 2021 | $607.58M |
| Dec 31, 2020 | $4.00 | $4.20 | $3.82 - $5.10 | -4.76% | Miss | -9.5% | 18 | N/A | Feb 23, 2021 | $665.52M |
| Sep 30, 2020 | $4.31 | $4.08 | $3.92 - $4.34 | +5.64% | Beat | +5.1% | 17 | N/A | Nov 2, 2020 | $600.89M |
| Jun 30, 2020 | $3.71 | $3.11 | $1.71 - $3.67 | +19.29% | Beat | -8.4% | 16 | N/A | Aug 4, 2020 | $562.44M |
| Mar 31, 2020 | $0.45 | $0.67 | $0.31 - $1.14 | -32.84% | Miss | -87.7% | 15 | N/A | May 5, 2020 | $534.73M |
| Dec 31, 2019 | $4.42 | $4.12 | $3.93 - $4.33 | +7.28% | Beat | +21.4% | 17 | N/A | Feb 25, 2020 | $581.74M |
| Sep 30, 2019 | $4.10 | $3.59 | $3.48 - $3.76 | +14.21% | Beat | +14.5% | 16 | N/A | Nov 5, 2019 | $537.70M |
| Jun 30, 2019 | $4.05 | $3.57 | $3.35 - $3.69 | +13.45% | Beat | +16.0% | 17 | N/A | Aug 6, 2019 | $534.13M |
| Mar 31, 2019 | $3.67 | $3.16 | $2.96 - $3.51 | +16.14% | Beat | +23.2% | 16 | N/A | May 7, 2019 | $508.19M |
| Dec 31, 2018 | $3.64 | $3.02 | $2.81 - $3.36 | +20.53% | Beat | +23.4% | 18 | N/A | Feb 26, 2019 | $476.46M |
| Sep 30, 2018 | $3.58 | $3.32 | $3.14 - $3.47 | +7.83% | Beat | +11.2% | 18 | N/A | Nov 6, 2018 | $469.37M |
| Jun 30, 2018 | $3.49 | $3.21 | $3.11 - $3.35 | +8.72% | Beat | +36.3% | 21 | N/A | Aug 7, 2018 | $500.48M |
| Mar 31, 2018 | $2.98 | $2.78 | $2.54 - $3.08 | +7.19% | Beat | +29.0% | 22 | N/A | May 8, 2018 | $444.61M |
| Dec 31, 2017 | $2.95 | $2.98 | $2.76 - $3.56 | -1.01% | Miss | +8.9% | 23 | N/A | Feb 27, 2018 | $436.40M |
| Sep 30, 2017 | $3.22 | $2.89 | $2.78 - $3.01 | +11.42% | Beat | +25.3% | 20 | N/A | Nov 7, 2017 | $411.86M |
| Jun 30, 2017 | $2.56 | $2.75 | $2.63 - $2.89 | -6.91% | Miss | -2.7% | 16 | N/A | Aug 8, 2017 | $394.39M |
| Mar 31, 2017 | $2.31 | $2.34 | N/A | -1.28% | Miss | +2.2% | N/A | N/A | May 9, 2017 | $376.05M |
| Dec 31, 2016 | $2.71 | $2.65 | N/A | +2.26% | Beat | +4.2% | N/A | N/A | Feb 28, 2017 | $396.62M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $7.06, down 66.7% from the year before. It was $10.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $7.06 | -66.7% |
| Dec 31, 2024 | $21.19 | +15.7% |
| Dec 31, 2023 | $18.32 | +39.5% |
| Dec 31, 2022 | $13.13 | -19.1% |
| Dec 31, 2021 | $16.23 | +30.2% |
| Dec 31, 2020 | $12.47 | -23.2% |
| Dec 31, 2019 | $16.24 | +18.6% |
| Dec 31, 2018 | $13.69 | +24.0% |
| Dec 31, 2017 | $11.04 | +8.6% |
| Dec 31, 2016 | $10.17 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,100 words across 21 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,122 | 21 | |
| 2026Q2 | Jun 30, 2026 | 6,424 | 21 | |
| 2026Q1 | Mar 31, 2026 | 8,008 | 18 | |
| 2025Q4 | Dec 31, 2025 | 8,122 | 19 | |
| 2025Q3 | Sep 30, 2025 | 7,914 | 22 | |
| 2025Q2 | Jun 30, 2025 | 9,087 | 20 | |
| 2025Q1 | Mar 31, 2025 | 8,903 | 20 | |
| 2024Q4 | Dec 31, 2024 | 9,592 | 19 |
2026Q3 Earnings Call
Opening remarks
John Bluth Head of Investor Relations Thank you, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its third quarter 2026 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website, along with the press release and quarterly report on Form 10-Q for the quarter ended September 30, 2026. On the call today are Renee Gala, President and Chief Executive Officer; Sam Pearce, Chief Commercial Officer; Robbie Iannone, Global Head of R&D and Chief Medical Officer; and Phil Johnson, Chief Financial Officer. On Slide 2, I'd like to remind you that today's webcast includes forward-looking statements, such as those related to our future financial and operating results, growth potential and anticipated development, regulatory and commercial milestones, which involve risks and uncertainties that could cause actual events, performance and results to differ materially from those contained in these forward-looking statements. We encourage you to review these risks and uncertainties described in today's press release and under the caption Risk Factors in our annual report on Form 10-K for the fiscal year ended December 31, 2025, and quarterly report on Form 10-Q for the quarter ended September 30, 2026. We undertake no duty or obligation to update our forward-looking statements. Furthermore, we will discuss non-GAAP financial measures on this webcast. Descriptions of these non-GAAP financial measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release and the slide presentation available on the Investors section of our website. I'll now turn the call over to Renee.
Renée Galá President and Chief Executive Officer Thank you, John. Good afternoon, everyone, and thank you for joining us today. Our third quarter results demonstrate the progress we are making as we build a more innovative and diversified Jazz. We delivered record revenues of $1.24 billion, an increase of 10% year-over-year, while advancing several important drivers of our future growth. Most notably, the FDA approval and launch of Ziihera in first-line HER2-positive metastatic GEA was a defining milestone for Jazz, establishing an important new source of growth and marking the beginning of what we believe could be a much broader opportunity across HER2-expressing cancers. And as you'll hear from Sam, the launch is off to a fantastic start. Longer-term data presented at ESMO further strengthen our conviction in Ziihera, and we continue to see peak sales potential of $3 billion to $5 billion. Our commercial portfolio is performing well, with multiple products contributing to our growth. Oncology revenues grew 35% year-over-year, driven by the launches of Modeyso and Zepzelca in the first-line maintenance setting, while sustained demand for Xywav continued to underscore its durability and differentiation. Given our third quarter performance, we have increased our 2026 revenue guidance, as Phil will outline later in the call.
Frequently Asked Questions About JAZZ
When is Jazz Pharmaceuticals's next earnings date?
Jazz Pharmaceuticals's next earnings report is expected for Feb 22, 2027.
Did JAZZ beat earnings estimates last quarter?
Yes. Jazz Pharmaceuticals reported EPS of -$4.83 for the quarter ended Sep 30, 2026, above the -$5.18 estimate, a 6.76% surprise.
What EPS do analysts expect from JAZZ next quarter?
The consensus EPS estimate for Jazz Pharmaceuticals for the quarter ending Dec 31, 2026 is $7.12 from 22 analysts, with estimates from $5.19 to $13.32.
How often does JAZZ beat earnings estimates?
Jazz Pharmaceuticals beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +0.60%.
JAZZ pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts